Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variations

Efforts directed at improving potency and preparing structurally different TYK2 JH2 inhibitors from the first generation of compounds such as 1a led to the SAR study of new central pyridyl based analogs 2-4. The current SAR study resulted in the identification of 4h as a potent and selective TYK2 JH2 inhibitor with distinct structural differences from 1a. In this manuscript, the in vitro and in vivo profiles of 4h are described. The hWB IC50 of 4h was shown as 41 nM with 94% bioavailability in the mouse PK study.

Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization

We describe a phenotypic screening and optimization strategy to discover compounds that block intracellular checkpoint signaling in T-cells. We identified dual DGKα and ζ inhibitors notwithstanding the modest similarity between α and ζ relative to other DGK isoforms. Optimized compounds produced cytokine release and T-cell proliferation consistent with DGK inhibition and potentiated an immune response in human and mouse T-cells. Additionally, lead inhibitor BMS-502 demonstrated dose-dependent immune stimulation in the mouse OT-1 model, setting the stage for a drug discovery program.

The Discovery of BMS-737 as a Potent, CYP17 Lyase-Selective Inhibitor for the Treatment of Castration-Resistant Prostate Cancer

We report herein, the discovery of BMS-737 (compound 33) as a potent, non-steroidal, reversible small molecule inhibitor demonstrating 11-fold selectivity for CYP17 lyase over CYP17 hydroxylase, as well as a clean xenobiotic CYP profile for the treatment of castration-resistant prostate cancer (CRPC). Extensive SAR studies on the initial lead 1 at three different regions of the molecule resulted in the identification of BMS-737, which demonstrated a robust 83% lowering of testosterone without any significant perturbation of the mineralocorticoid and glucocorticoid levels in cynomologous monkeys in a 1-day PK/PD study.

Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype

We describe our efforts to introduce structural diversity to a previously described triazole-containing N1-carboline series of bromodomain and extra-terminal (BET) inhibitors. N9 carbolines were designed to retain favorable binding interactions that the N1-carbolines possess. A convergent synthetic route enabled modifications to reduce clearance, enhance physicochemical properties, and improve the overall in vitro profile. This work led to the identification of a potent BET inhibitor, (S)-2-{8-fluoro-5-[(3-fluoropyridin-2-yl)(oxan-4-yl)methyl]-7-[4-(²H₃)methyl-1-methyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-3-yl}propan-2-ol (10), a compound with enhanced oral exposure in mice. Subsequent evaluation in a mouse triple-negative breast cancer tumor model revealed efficacy at 4 mg/kg of N9-carboline 10.

Discovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase

C-terminal Src kinase (CSK) functions as a negative regulator of T cell activation through inhibitory phosphorylation of LCK, so inhibitors of CSK are of interest as potential immuno-oncology agents. Screening of an internal kinase inhibitor collection identified pyridazinone lead 1, and a series of modifications led to optimized compound 13. Compound 13 showed potent activity in biochemical and cellular assays in vitro and demonstrated the ability to increase T cell proliferation induced by T cell receptor signaling. Compound 13 gave extended exposure in mice upon oral dosing and produced a functional response (decrease in LCK phosphorylation) in mouse spleens at 6 h post dose.

Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis

The four members of the Janus family of nonreceptor tyrosine kinases play a significant role in immune function. The JAK family kinase inhibitor, tofacitinib 1, has been approved in the United States for use in rheumatoid arthritis (RA) patients. A number of JAK inhibitors with a variety of JAK family selectivity profiles are currently in clinical trials. Our goal was to identify inhibitors that were functionally selective for JAK1 and JAK3. Compound 22 was prepared with the desired functional selectivity profile, but it suffered from poor absorption related to physical properties. Use of the phosphate prodrug 32 enabled progression to a murine collagen induced arthritis (CIA) model. The demonstration of a robust efficacy in the CIA model suggests that use of phosphate prodrugs may resolve issues with progressing this chemotype for the treatment of autoimmune diseases such as RA.

Abstract B284: Discovery of imidazopyridazinecarbonitriles as potent, selective inhibitors of CK2

Casein kinase 2 (CK2) is a serine/threonine kinase that has been implicated in the regulation of a number of oncogenic or tumor suppressor proteins. CK2 activity has been shown to be elevated in numerous studies in a variety of cancer types. CK2 has been shown to phosphorylate numerous cellular proteins. Among the proteins regulated directly or indirectly by CK2 phosphorylation are oncogenes and tumor suppressor proteins including beta-catenin, c-Myc, PML, and PTEN as well as proteins directly involved in cell cycle, apoptosis, and transcriptional regulation. The plethora of CK2 substrates and their participation in various cellular processes is a major confounding factor in understanding the role of CK2 in oncogenesis. Unlike other kinase targets that participate in relatively linear growth factor signaling pathways, CK2 appears to function more “laterally,” across many important signaling pathways to promote growth and survival of cancer cells. It is clear from numerous studies using siRNA as well as small molecule CK2 inhibitors that cancer cells are highly dependent upon CK2 for growth and survival. As a result, new small molecule inhibitors of CK2 may provide useful tools for probing CK2 biology and may also provide therapeutic benefits against several cancer types. Herein, we report our efforts toward the identification of CK2 inhibitors based on an imidazopyridazine carbonitrile scaffold. Lead compounds from this series demonstrate low nanomolar CK2 biochemical potency, while achieving excellent selectivity versus the majority of kinases in the human kinome. The development of structure-activity relationships and the establishment of a strong correlation between biochemical potency, inhibition of cellular protein target phosphorylation and anti-proliferative effects in targeted cancer cell lines will be presented. In addition, the optimization of pharmacokinetic properties resulting in compounds with excellent in vivo exposure has allowed for the investigation of CK2 inhibition in a pharmacodynamic model. Finally, our efforts to elucidate pathway effects mediated by CK2 in model colon cancer cell lines, including gene expression profiling using advanced small molecules leads, will be disclosed.

Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B284.

Citation Format: Brian Fink, Ashvinikumar Gavai, Soong-Hoon Kim, Yufen Zhao, Ashok Purandare, Gregory Vite, John Tokarski, Chiang Yu, Benjamin Henley, Joseph Fargnoli, Heshani Desilva, Petra Ross-MacDonald, Brent Rupnow, Tai W. Wong. Discovery of imidazopyridazinecarbonitriles as potent, selective inhibitors of CK2. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B284.

Abstract DDT01-03: Discovery of BMS-911543, a highly selective JAK2 inhibitor, as a clinical candidate for the treatment of myeloproliferative disease and other malignancies

Myeloproliferative diseases (MPDs) are a subset of myeloid malignancies that are characterized by the expansion of a multipotent hematopoietic stem cell. Chronic MPDs can be classified into two categories, those harboring the BCR-ABL oncogene and those that are negative. This later category of neoplasms encompasses polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Recent discovery of activating mutations in the tyrosine kinase gene, JAK2 and constitutive activation of JAK2-STAT pathway, in large number of MPD patients has ignited considerable interest in MPD and has highlighted JAK2 as a therapeutic intervention point for drug discovery efforts. However, high-sequence homology with other JAK family members has posed a major challenge to design selective JAK2 inhibitors. Given that other JAK family members are involved in the regulation of immune function, it is important to maintain selectivity for JAK2 over these family members in order to mitigate the risks associated with undesired immunosuppression. Several JAK2 inhibitors with varying selectivity profiles are currently being evaluated in preclinical testing as well as in clinical trials for the treatment of MPD. Additionally, emerging genetic and pharmacologic evidence suggest that inhibition of the JAK2-STAT pathway may be an important therapeutic intervention point in other hematological malignancies as well as in certain solid tumors.

We report here the discovery and characterization of BMS-911543, a functionally selective small molecule inhibitor of the Janus kinase family (JAK) member, JAK2. BMS-911543 is a potent and reversible inhibitor of JAK2 with a biochemical Ki of 0.48 nM. It has over 65-, 74- and 350-fold selectivity against the other JAK family members, TYK2, JAK3 and JAK1, respectively. Importantly, examination of > 450 other kinases in competition binding assays and in selected biochemical kinase assays did not reveal significant inhibitory activity for this JAK2 inhibitor, highlighting its high degree of biochemical selectivity for JAK2.

Functionally, BMS-911543 displayed potent antiproliferative and pharmacodynamic (PD) effects in mutated JAK2-expressing cell lines dependent upon JAK2-STAT signaling and had little activity in cell types dependent upon other pathways such as JAK1 and JAK3. Further, single agent antiproliferative activity was not observed for BMS-911543 in a variety of solid tumor cell lines dependent upon other signaling pathways. In contrast, BMS-911543 was evaluated in colony growth assays using primary progenitor cells isolated from patients with JAK2V617F-positive myeloproliferative disease (MPD) and resulted in an increased antiproliferative response in MPD cells as compared with those from healthy volunteers. Similar to these in vitro observations, BMS-911543 was also highly active in in vivo models of JAK2-pSTAT signaling in multiple species with durable and potent pathway suppression observed after a single oral dose. Additionally, BMS-911543 was evaluated for effects in a JAK2V617F-expressing SET-2 xenograft model system and displayed a minimally effective dose of <2 mg/kg on pSTAT5 pathway suppression, which lasted up to 8 hours.

To test the hypothesis that a JAK2 selective inhibitor would have less effect on immune system function, BMS-911543 was compared to pan-JAK inhibitors in a mouse model of immunosuppression. At low dose levels active in JAK2-dependent PD models, no effects were observed on antigen-induced IgG and IgM production for BMS-911543 whereas a pan-JAK family inhibitor showed pronounced effects at all dose levels tested. The mechanistic selectivity of BMS-911543 to pan-JAK family inhibitors was extended through comparative analysis of these inhibitors in whole genome gene expression profiling experiments performed in sensitive and resistant cell types. In this comparison, BMS-911543 modulated a distinct subset of transcriptional changes as compared to pan-JAK inhibitors in clinical testing, thereby defining a minimal set of transcriptional changes underlying the pharmacologic effects of JAK2 inhibition. Collectively these results define the mechanistic basis for a differential therapeutic index between selective JAK2 and pan-JAK family inhibition pre-clinically and suggest a therapeutic rationale for the further characterization of BMS-911543 in patients with MPD and in other malignancies reliant upon constitutively active JAK2 signaling.

References:

Levine, R.L., et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders (2007). Nature Rev. Cancer, 7, 673-683.

Atallah, E. and Verstovsek, S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. (2009). Expert Rev. Anticancer Ther. 9, 663-670.

Ghoreschi, K., et al. Janus kinases in immune cell signaling. (2009). Immunol. Rev.,228, 273-287.

Mesa, R.A. and Tefferi, A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis (2009). Expert Opin. Emerging Drugs, 14, 1-9.

Roll, J.D. and Reuther, G.W. CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. (2010) Cancer Res, 70, 7347-7352.

Rui et al., Cooperative epigenetic modulation by cancer amplicon genes (2010). Cancer Cell, 18, 590-605.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr DDT01-03. doi:10.1158/1538-7445.AM2011-DDT01-03

Amphetamine enhances natural killer cytotoxic activity via beta-adrenergic mechanism

Although addiction to amphetamine (AMPH) is a serious social and medical problem, the data concerning AMPH - immune interactions are still not numerous. To analyze the mechanism of AMPH-induced changes in the function of the immune system, rats were pretreated with beta-adrenergic receptor antagonist propranolol (PROP; 5 mg/kg, i.p.) prior to AMPH (1 mg/kg, i.p.) administration. Natural Killer cells cytotoxicity (NKCC) ((51)Cr-release assay), the number of LGLs (NK cells) (Timonen method), leukocytes, lymphocytes and monocytes, and plasma corticosterone level (CORT) (RIA) were evaluated in the peripheral blood and spleen. In the peripheral blood increases in NKCC (+331 Delta %), as well as in LGL (+33 Delta %) and monocyte (+65 Delta %) number observed after AMPH were partially inhibited by PROP (respectively by 30%, 19%, and 30%) in contrast to lymphopenia (-19 Delta %) and granulocytosis (+65 Delta %) which were not affected by beta-blockade. In the spleen AMPH-induced decreases in NKCC (-25 Delta %) and in all the leukocyte populations number (approximately -30 Delta %) were completely blocked by PROP. Plasma CORT level, highly elevated by AMPH (+337 Delta %), was attenuated nearly by 50% under beta-adrenergic blockade. These data indicate that AMPH-induced enhancement of cytotoxic activity of NK cell is related to beta-adrenergic mechanism.

Stress-induced enhancement of activity of lymphocyte lysosomal enzymes in pigs of different stress-susceptibility

To evaluate a possible mechanism of stress-induced lymphopenic effect we assessed the activity of lymphocyte lysosomal enzymes (LE) under immobilization. The effects of immobilization stress on LE (AP, acid phosphatase, cathepsin D and L, beta-N-acetyl-glucosamidase) activity in lymphocytes, number of lymphocytes and plasma cortisol (COR) level in the peripheral blood were examined in the cross-bred Pietrain pigs showing genotypic (presence or lack of RyR1 gene mutation) and phenotypic (reactivity to halothane) differences. It was found that immobilization stress evoked an increase in LE which was concomitant with lymphopenia and a rise of COR level. The most pronounced enhancement of LE, which may reflect a tendency to lymphocyte cytolysis, was found in the recessive homozygotes RyR1 (nn) phenotypically defined as stress/halothane susceptible as well as in the heterozygotes RyR1 (Nn) included in the group of stress/halothane resistant. Despite this individual variability the stress-induced increase in LE activity was present in all the animals. It seems that a possibility of destruction (lysis) of lymphocyte cells should not be excluded as one of the causes of stress lymphopenia.

Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion assay. BMS-316810 (9e), a 0.7 nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study.

Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors

A versatile synthesis of the suitably functionalized pyrrolo[2,1-f][1,2,4]triazine nucleus is described. SAR at the C-5 and C-6 positions of the 4-(3-hydroxy-4-methylphenylamino)pyrrolo[2,1-f][1,2,4]triazine template led to compounds with good in vitro potency against VEGFR-2 kinase. Glucuronidation of the phenol group is mitigated by incorporation of a basic amino group on the C-6 side chain of the pyrrolotriazine nucleus.

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays

A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays

A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.

Blood and spleen natural killer cell cytotoxicity after exposure to open field stress in rats: the effect of spontaneous locomotor activity

In the present study we compared the effects of acute (30 min), white and illuminated open field (OF) stress on behavioral, immune and endocrine variables between rats divided into high (HR) and low (LR) responsive to novelty and in a non-divided group. It was found that OF-induced behavioral depression which was in parallel to suppression of both blood and spleen natural killer cell cytotoxicity (NKCC), large granular lymphocyte (LGL) and lymphocyte numbers occurred in stressed LR rats only. There was no significant difference in the plasma level of corticosterone (COR) and testosterone (TST) between HR and LR rats. In contrast, when the HR and LR groups were examined together (the non-divided group), no significant influence of OF stress on behavioral activity or NKCC was observed. These results emphasize that individual differences as measured by spontaneous locomotor activity play the important role for the study of the mechanisms involved in stress-induced immunomodulation and indicate that OF stress-induced behavioral depression in low reactivity animals may be accompanied by impaired defence against viral infections and neoplastic growth, which is functionally related to NKCC.

Peripheral blood natural killer cell cytotoxicity after damage to the limbic system in the rat

The present work was aimed at examining the possible involvement of different parts of the septal area (dorsal, medial, lateral, and septohypothalamic nucleus), the basolateral amygdala, and the bed nucleus of the stria terminalis (BNST) in the regulation of the cytotoxic activity of NK cells (NKCC). The experimental approach included performing electrolytic (or sham) lesions in the tested brain areas and to measuring the peripheral blood NKCC (chromium-51 release assay), the number of leukocytes and lymphocytes, and the plasma corticosterone levels both before and at different time points after the lesion. Lesions were also induced in the three extralimbic structures: the paraventricular hypothalamic nucleus (PVN), the dorsal caudate-putamen, and the cerebellum. To test for a possible effect on NKCC of stress associated with blood collection, anesthesia, cranial surgery, and passing electric current through the brain the proper control experiments were also performed. Lesions of the medial septum and BNST caused gradual depression of NKCC, which peaked on the 10th day after the lesion, followed by a recovery to the baseline on days 21 (medial septum) and 42 (BNST) postinjury. In the respective sham-lesioned groups, mere insertion of electrodes into the medial septum and BNST evoked transient enhancement of NKCC (on the 3rd postlesion day), probably resulting from mechanical stimulation of the nervous tissue. Destruction of the other limbic and extralimbic structures appeared ineffective. After PVN lesions NKCC remained unchanged, despite an approximately 60% decrease in the basal corticosterone level. No adverse effects of the experimental and surgical procedures on NKCC, leukocyte and lymphocyte number, and corticosterone level were found, indicating that electrolytic lesions and other stereotaxic techniques can be safely used to study the brain-immune system interactions. The results obtained raise the question about the interrelationship between the medial septum and the hippocampal formation, BNST, the medial amygdala, and the hypothalamus (both medial and lateral) as a possible circuit involved in the regulation of cellular immune functions.

Stress-induced changes in peripheral natural killer cell cytotoxicity in pigs may not depend on plasma cortisol

The study examined cortisol (COR) involvement in stress-related changes in natural killer cell cytotoxicity (NKCC). The relationship between blood COR level, phasic changes in NKCC, and the number of large granular lymphocytes (LGL) was examined in pigs during the course of 4-h immobilization stress (IMB) and for 6 days after its termination. NKCC was determined using 18-h 51Cr-release assay, LGL number was assessed with a standard hematological method, and plasma COR level was measured by radioimmunoassay. The blood level of COR was increasing during IMB (max 446Delta% at the second hour) and decreased after its termination (max -59Delta% on day 2). Changes in NKCC level and LGL number were biphasic; i.e., an initial increase in both measures (NKCC max 24Delta%, LGL max 18Delta%) in an early phase of stress (0-1h) was followed by their subsequent decrease (NKCC max -35Delta%, LGL max -41Delta%) in the late phase (3-4 h) of stress, which persisted for several days after termination of IMB. Thus, in the early phase of stress, there was a positive correlation between NKCC, LGL number, and COR levels (all elevated); a positive correlation between the measures also occurred after termination of IMB (all decreased). A negative correlation between COR and NKCC, which might be indicative of COR-related immunosuppression, was found only in the late (3-4 h) phase of stress. It is concluded that COR may be only one of multiple factors (possibly antagonistic) determining an actual immune response during stress.

Synthesis, structure proof, and biological activity of epothilone cyclopropanes

[structure--see text] A semisynthetic route to epothilone cyclopropanes from epothilones A and B is described. Of significance, the deoxygenation of the 12, 13-epoxide to give the corresponding olefin was achieved with high efficiency. The title compounds (8, 9) were active in both tubulin polymerization and cytotoxicity assays, which is in direct contrast to a previously published report. These results provide further evidence that the role of the 12,13-epoxide of epothilones is largely conformational and argue against some of the current pharmacophore models.

Anatomical correlates of the lateral hypothalamic influence on waking-sleep relationship in the rat

Restricted electrolytic lesions of the lateral hypothalamus (LH) evoke sleeplessness in the rat. The present study was aimed to analyze a possible anatomical substrate of the LH hyposomnia within the hypothalamus. In a group of electrolytically lesioned LH rats the intensity of sleep disturbances, assessed on the basis of EEG records from the neocortex and the hippocampus, was confronted with the localization and the extent of destruction of the LH area and with the topography of known fiber systems of the medical forebrain bundle (MFB). In separate experiments the effects of the destruction of LH cell bodies by means of bilateral ibotenic acid (IBO) injections and inhibition of LH neuronal elements by bilateral muscimol (MUSC) administration were also tested. It was found that pronounced hyposomnia follows electrolytic but not IBO lesions of the LH/MFB area. The effective LH damage might have been localized at every level of its antero-posterior axis, from the preoptic area up to the posterior hypothalamus, suggesting involvement of fiber system(s) rather than a localized group of neuronal pericaria. The most effective lesions transsected projections descending from the preoptic/anterior hypothalamic area, olfactory structures, ventral striatum and the central amygdaloid nucleus as well as fibers connecting LH with the brainstem reticular formation, many of them using GABA as a neurotransmitter. Bilateral MUSC injections caused a dose-dependent, bicuculline-reversible, increase in waking time, most pronounced at a dose of 50 ng, which ressembled the effect of the electrolytic lesion. These results indicate that LH hyposomnia is not attributable to the damage to the intrahypothalamic neurons and suggest the participation of GABA-ergic transmission in LH in waking-sleep regulation.

Effect of lateral hypothalamic lesion on sleep-waking pattern and EEG power spectra in the rat

Bilateral, electrolytic lesion of the lateral hypothalamus (LH) in rats produces hyposomnia and qualitative EEG changes which are difficult to assess by conventional visual inspections of electroencephalograms. In the present study the spectral analysis of EEG was applied in LH-lesioned rats and confronted with a standard visual scoring method. One-hour samples of hippocampal and cortical EEG were taken from the light part of the circadian cycle before and after electrolytic or sham LH damage. In half of the LH-lesioned rats a power spectral analysis was performed using a Fast Fourier Transform routine at 1 Hz bands from 0.5 to 25 Hz; in the other half, as well as in the sham-lesioned group, EEG records were visually scored for the amount of waking, slow wave sleep and paradoxical sleep. Significant hyposomnia effects were found in LH-lesioned rats. Power spectral analysis of hippocampal EEG revealed a significant increase in power density at 4-6 Hz and a reduction at 7-10, 14-17, 19-22 and 23-24 Hz. In neocortical EEG there was a significant increase in power density at 5-6 Hz band and a reduction at 7-8 Hz. The results are discussed in the context of the effects of selective destruction of the specific neurotransmitter systems occupying the LH area.

Electrolytic lesions of the lateral hypothalamus influence peripheral blood NK cytotoxicity in rats

Bilateral electrolytic lesions of the lateral hypothalamic (LH) area in Wistar rats result in a time-dependent blood NK cytotoxicity changes as measured by the 51Cr-release (for entire cell population) and agarose (for a single-cell) assays. NK activity against YAC-1 and K-562 cells shifts from depression through enhancement to another depression on the 2nd, 5th and 21st post-lesion day, respectively, as compared to both LH sham-operated animals and the pre-lesion baselines. This effect is not attributable to malnutrition and dehydration resulting from ingestive impairments evoked by LH lesions. No significant change in NK cytotoxicity was found after destruction of the medial hypothalamus (MH). The results indicate that LH, under normal conditions, which may be considered as a dynamogenic and stressogenic hypothalamic area is essential for proper regulations of NK cytotoxicity at both population and single-cell level.

Daily pattern of EEG activity in rats with lateral hypothalamic lesions

The experiment was aimed to further elucidate the phenomenon of sleep suppression observed earlier after electrolytic lesions of the lateral hypothalamus (LH). In male Wister rats the amounts of waking (W), slow wave sleep (SWS) and paradoxical sleep (PS) were counted in 1 h samples of EEG taken from the light and dark parts of the circadian cycle, as well as in the whole 12 h diurnal records before lesioning and after electrolytic or sham lesions of LH. Significant increase of W with a simultaneous reduction of SWS and PS was found in 1h and 12h diurnal records; no effect of the lesion on nocturnal EEG was observed. The results suggest that lesion-induced sleep suppression concerns the light part of the day when rats are naturally less active, and that 1h samples of diurnal EEG may be sufficient to diagnose LH insomnia. No correlation was found between the magnitude of waking-sleep disturbances and the intensity of ingestive impairments (aphagia, adipsia, body weight loss) evoked by LH lesions which suggests that LH insomnia may be a result of disruption of a mechanism directly involved in the regulation of waking-sleep cycle rather than a secondary effect of other lesion-induced impairments.

Molecular shape and QSAR analyses of a family of substituted dichlorodiphenyl aromatase inhibitors

Conformational analyses of three families of substituted dichlorodiphenyl aromatase inhibitors indicated that both potent and weak inhibitors adopt a common global minimum energy conformation. Further, this global minimum energy conformation is the only meaningful intramolecular conformer state that can be energetically realized and is virtually identical to the crystal structure of one of the analogs. Quantitative structure-activity relationships, QSARs, were separately, and jointly, developed for two series of inhibitors. The distance, D, of a nitrogen atom in the variable heterocycle from the core Cc atom is the most important activity descriptor. The optimum distance between the nitrogen and Cc to maximize inhibitor potency is about 3.6 A for both classes of analogs. Integrated potential energy field difference calculations were also carried out using a proton probe and some of the variable heterocycles. The field calculations coupled with the QSAR studies suggest that the nitrogen 3.6 A from Cc acts as a hydrogen bond acceptor. Two possible three-dimensional pharmacophores are proposed for effective aromatase inhibitors.

The influence of immobilization stress on natural killer cytotoxic activity in halothane susceptible and resistant pigs

In halothane-susceptible (Hal+) and halothane-resistant (Hal-) Belgian Landrace pigs, the influence of immobilization stress on cytotoxic activity of natural killer (NK) cells was evaluated. Four hour immobilization causes biphasic changes in cytotoxicity, i.e. an initial increase followed by a subsequent depression. In both groups of pigs stress-induced suppression of NK cell activity lasted for several days in the post stress period. Throughout the experiment, i.e. before, during and after stress, the level of cytotoxicity was higher in Hal+ than in Hal- pigs.

The EEG activity after lesions of the diencephalic part of the zona incerta in rats

Neocortical and hippocampal EEG activity was recorded in 23 rats subjected to the bilateral electrolytic lesions of the diencephalic zona incerta (ZI). The aim was to find whether damage to ZI can replicate insomnia and disturbances in cortical EEG desynchronization and hippocampal theta rhythm found after lesions of the lateral hypothalamic (LH) area. No effect of the ZI lesions on waking-sleep cycle was found. The amplitude and frequency of cortical waves and hippocampal theta rhythm during waking were changed only in some rats. These changes were small, short-lasting and bidirectional (toward and increase or decrease in different subjects). Both the amplitude and frequency of paradoxical sleep theta were depressed in part of animals. Thus the marked EEG changes after LH lesions can not be attributed to simultaneous damage of the adjacent subthalamic region. However, the ZI seems to constitute a part of a larger system regulating cortical arousal and hippocampal theta rhythm.

[Meningomyelocele with spinal cord cyst and internal hydrocephalus in a 9-month-old boy]

The authors describe a boy aged 9 months with open myelomeningocele which changed gradually into meningocele with spinal cord cyst. During treatment internal hydrocephalus developed requiring insertion of Pudenz-Heyer ventriculoatrial. valve. The treatment was successful. The case illustrates the succession of changes which may develop in myelomeningocele and the relationship between the state of internal hydrocephalus and the volume of meningocele and spinal cyst (cerebrospinal fluid production exceeding its resorption).

A system of pre-forming of physiological processes for automatic frequency analysis

The system described was designed for automatic frequency analysis during considerable amplitude oscillations as well as changes in the shape and interferences of the signal examined. The system was connected with ANOPS-101 digital computer.¿